Profile of Bent Jakobsen
Dr Bent Jakobsen is the scientific co-founder of Adaptimmune, focused on the use of T cell therapy to treat cancer. Adaptimmune traces its roots back to Avidex, founded by Bent in 1999 as a spin-out from the University of Oxford, whilst at the Institute of Molecular Medicine (IMM). Bent was head of the Immune Receptor Group at the IMM from 1993 to July 2000. Avidex was acquired by Medigene AG in October 2006 and, in early 2008, Adaptimmune was formed.
